Belvedere Trading
RVMD icon

Belvedere Trading’s Revolution Medicines RVMD Stock Holding History

Belvedere Trading’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-9,792
Closed -$274K – 601
2021
Q3 		$274K Buy
+9,792
New +$285K 0.01% 199

Other funds holding RVMD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Belvedere Trading's RVMD Position: Q4 2021 in Review

Belvedere Trading sold out of Revolution Medicines (RVMD) in Q4 2021, closing a stake of 9,792 shares — an estimated $274K sold.

Belvedere Trading first reported a position in RVMD in Q3 2021 and held it in 1 quarter. The position peaked at $274K in Q3 2021. 117 funds tracked by Wall St. Rank hold RVMD as of Q4 2021.

  • Belvedere Trading reported no remaining Revolution Medicines position as of Q4 2021 after selling out during the quarter.
  • Belvedere Trading sold 9,792 Revolution Medicines shares in Q4 2021, an estimated $274K.
  • Belvedere Trading first reported a position in Revolution Medicines in Q3 2021 and held it in 1 quarter.
  • Belvedere Trading's Revolution Medicines position peaked at $274K in Q3 2021.
  • 117 funds tracked by Wall St. Rank held Revolution Medicines as of Q4 2021.

Based on Belvedere Trading's 13F filing for Q4 2021, filed 25 Jan 2022.